Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Seamless Clinical Study Evaluating the Efficacy, Safety, PK, PD, and ADA of MG-K10 Humanized Monoclonal Antibody Injection in the Treatment of Seasonal Allergic Rhinitis

NCT06846385 is registered in ClinicalTrials.gov with Shanghai Mabgeek Biotech.Co.Ltd as lead sponsor.

NCT NCT06846385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06846385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Seamless Clinical Study Evaluating the Efficacy, Safety, PK, PD, and ADA of MG-K10 Humanized Monoclonal Antibody Injection in the Treatment of Seasonal Allergic Rhinitis
Lead sponsor
Shanghai Mabgeek Biotech.Co.Ltd
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 20, 2025
Completion date
September 30, 2025
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

seasonal allergic rhinitis